Century Therapeutics, Inc.
IPSC
: Overview: We are a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Our beta islet, T cell and NK cell programs are allogeneic, meaning they are derived from healthy donors for use in any patient, rather than being sourced from a…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (FY)
$109M
▲ +1556.8% YoY
Net Income (TTM)
-$99M
▲ +92.4% YoY
Op. Margin
-15.82%
▲ +2080.7pp YoY
ROIC
-32.43%
▲ +42.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$85M
▲ +5.0% YoY
Op. Cash Flow (TTM)
-$83M
▲ +5.7% YoY
Net Debt
-$80M
Net Cash Position
Cash & Equiv.
$117M
3Y CAGR: +175.9%
Continue Research
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with IPSC
Held by ETFs
IPSC is in 2 US ETFs. The largest of them, with IPSC's weight in each:
Century Therapeutics (IPSC) in four numbers
Questions about Century Therapeutics
Is Century Therapeutics (IPSC) overvalued?
At $1.38, Century Therapeutics' price is 79% below the $6.51 a share fair value that Intrinsiqq's calculator gets from its revenue. The growth behind that figure is yours to set on the Intrinsic Value tab. See how to tell if a stock is overvalued.
What is Century Therapeutics' fair value?
Intrinsiqq's calculator puts Century Therapeutics' fair value at $6.51 a share. It grows revenue per share 30% a year for 5 years, applies an exit P/S of 4.7, and works back at a 10% yearly return. A 25% margin of safety gives a buy-below price of $4.89. Every input can be changed on the Intrinsic Value tab.
Is Century Therapeutics a high-quality business?
Century Therapeutics scores 40 out of 100 on Intrinsiqq's quality score, which makes it a mixed business on these measures. The score blends 6 checks computed from SEC filings. Its best check is revenue growth at 175.9%, and its weakest is return on capital at -32.4%. The Quality tab shows every check against its target.
Does Century Therapeutics (IPSC) pay a dividend?
No. Century Therapeutics (IPSC) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 5 Nov 2026 (period ending 30 Sept 2026), SEC. Price: live 17 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in IPSC's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing IPSC
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.